Preliminary Results from a Phase II Study to Evaluate the Efficacy and Safety of Perioperative Disitamab Vedotin (RC48-ADC) Plus Cadonilimab (AK104, PD-1/CTLA-4 Bispecific Antibody) for HER2-expressing Muscle-Invasive Bladder Cancer (MIBC).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined